Keywords: Blood Vessels, Neurodegeneration, Myelin Water Imaging
Motivation: Thrombotic Thrombocytopenic Purpura patients suffer from high risk of cognitive related complications post-remission that can decrease quality-of-life and in some cases death.
Goal(s): We investigate a new treatment drug Caplacizumab to determine whether it can reduce neurocognitive burden.
Approach: We use quantitative MRI and CT-perfusion to investigate patients that have received Caplacizumab to patients that have not. MRI and CT data look at a variety of different metrics to investigate brain health.
Results: Preliminary results from CT-perfusion indicate better blood brain barrier recovery in Caplacizumab group, which may decrease cognitive burden. MRI results show significant decrease of myelin in patients without Caplacizumab.
Impact: The results of this study can open the door for a new treatment for Thrombotic Thrombocytopenic Purpura patients that may ensure they do not suffer from cognitive decline or cerebrovascular disease related death.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords